Next Article in Journal
Association of Pertussis Toxin with Severe Pertussis Disease
Next Article in Special Issue
Suppressive Effects of Bee Venom-Derived Phospholipase A2 on Mechanical Allodynia in a Rat Model of Neuropathic Pain
Previous Article in Journal
Exposure to the Harmful Algal Bloom (HAB) Toxin Microcystin-LR (MC-LR) Prolongs and Increases Severity of Dextran Sulfate Sodium (DSS)-Induced Colitis
Previous Article in Special Issue
Comparison of the Protective Effects of Bee Venom Extracts with Varying PLA2 Compositions in a Mouse Model of Parkinson’s Disease
Review

From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent

1
Department of Medicine, Mackay Medical College, New Taipei City 25245, Taiwan
2
Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
*
Author to whom correspondence should be addressed.
Received: 2 June 2019 / Revised: 22 June 2019 / Accepted: 24 June 2019 / Published: 26 June 2019
(This article belongs to the Special Issue From Toxins to Drugs)
Snake venoms affect blood coagulation and platelet function in diverse ways. Some venom components inhibit platelet function, while other components induce platelet aggregation. Among the platelet aggregation inhibitors, disintegrins have been recognized as unique and potentially valuable tools for examining cell–matrix and cell–cell interactions and for the development of antithrombotic and antiangiogenic agents according to their anti-adhesive and anti-migration effect on tumor cells and antiangiogenesis activities. Disintegrins represent a family of low molecular weight, cysteine-rich, Arg-Gly-Asp(RGD)/Lys-Gly-Asp(KGD)-containing polypeptides, which inhibit fibrinogen binding to integrin αIIbβ3 (i.e., platelet glycoprotein IIb/IIIa), as well as ligand binding to integrins αvβ3, and α5β1 expressed on cells (i.e., fibroblasts, tumor cells, and endothelial cells). This review focuses on the current efforts attained from studies using disintegrins as a tool in the field of arterial thrombosis, angiogenesis, inflammation, and tumor metastasis, and briefly describes their potential therapeutic applications and side effects in integrin-related diseases. Additionally, novel R(K)GD-containing disintegrin TMV-7 mutants are being designed as safer antithrombotics without causing thrombocytopenia and bleeding. View Full-Text
Keywords: snake venom proteins; disintegrins; antiplatelet agent; arterial thrombosis; angiogenesis; septic inflammation snake venom proteins; disintegrins; antiplatelet agent; arterial thrombosis; angiogenesis; septic inflammation
Show Figures

Figure 1

MDPI and ACS Style

Kuo, Y.-J.; Chung, C.-H.; Huang, T.-F. From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent. Toxins 2019, 11, 372. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11070372

AMA Style

Kuo Y-J, Chung C-H, Huang T-F. From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent. Toxins. 2019; 11(7):372. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11070372

Chicago/Turabian Style

Kuo, Yu-Ju, Ching-Hu Chung, and Tur-Fu Huang. 2019. "From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent" Toxins 11, no. 7: 372. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11070372

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop